检查单独生活的人与神经退行性疾病的挑战:一个范围审查协议的审查协议
Anthony Martyr1,2, Maria Caulfield2,3,4, Catherine Charlwood5,2,6
1Department of Health and Community Sciences, University of Exeter Medical School, Exeter, UK A.Martyr@exeter.ac.uk.
BMJ open
|June 11, 2025
概括
这次范围审查将综合证据,阐述单独生活在神经退行性疾病中的人所面临的挑战. 调查结果将有助于改善对这一弱势群体的卫生和社会护理服务.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 公共卫生 公共卫生
背景情况:
- 单独生活的患有神经退行性疾病的个人在保持独立性和获得支持方面遇到独特的挑战.
- 巩固当前的理解对于定制卫生和社会护理服务至关重要.
- 这篇评论侧重于孤独生活的痴呆症,帕金森病,亨廷顿病或运动神经元疾病患者.
研究的目的:
- 进行范围审查,总结现有证据,以了解孤独生活中患有神经退行性疾病的人所面临的困难.
- 发现当前研究中的差距,并为未来的研究提供信息.
- 为改善卫生和社会护理服务提供提供证据.
主要方法:
- 使用系统审查和元分析 (PRISMA) 和乔安娜·布里格斯研究所 (JBI) 方法论的首选报告项目.
- 在多个数据库 (PubMed,科学网络,CINAHL,AgeLine,EMBASE,PsycInfo,社会政策和实践) 和灰色文献中进行全面的文献搜索.
- 研究出版物的两阶段选过程 (标题/摘要,然后是全文),选顶部PDF的灰色文献.
主要成果:
- 数据综合将涉及对研究特征和发现进行表制.
- 叙述总结将确定共同的主题,研究差距和未来研究领域.
- 审查将综合证据,说明这一群体所面临的独特困难.
结论:
- 调查结果将为政策,实践和改进支持服务的开发提供信息.
- 咨询有实践经验的人将确保相关性和适用性.
- 通过政策报告和同行评审出版物进行传播,旨在增强单独生活的神经退行性患者的护理.
更多相关视频
11:21Methodology for Establishing a Community-Wide Life Laboratory for Capturing Unobtrusive and Continuous Remote Activity and Health Data
Published on: July 27, 2018
8.2K
06:52Assessment of Dependence in Activities of Daily Living Among Older Patients in an Acute Care Unit
Published on: September 30, 2020
9.7K
相关概念视频
01:29Documentation in Long-Term and Home Healthcare Setting
875
Documentation in long-term care facilities and home healthcare settings is crucial for ensuring continuous, coordinated, and comprehensive care for patients. Each setting has its specific documentation processes and tools:
Long-Term Care Facilities
Long-Term Care Facilities
875
01:26Alzheimer's Disease: Overview
454
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
454
01:30Dementia
107
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
107
01:15Parkinson's Disease: Overview
499
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
499
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170